Clinical drug research in chronic central neurodegenerative disorders

References

• Emmerzaal TL, Kiliaan AJ, Gustafson DR. A decade of body mass index, Alzheimer’s disease, and dementia. J Alzheimers Dis. 2003-2013:2015(43):739–755.
   Google Scholar
• Takizawa C, Thompson PL, van Walsem A, et al. Epidemiological and economic burden of Alzheimer’s disease: a systematic literature review of data across Europe and the United States of America. J Alzheimers Dis. 2015;43:1271–1284.
   PubMed Web of Science ®Google Scholar
• Frost B, Gotz J, Feany MB. Connecting the dots between tau dysfunction and neurodegeneration. Trends Cell Biol. 2015;25:46–53.
   PubMed Web of Science ®Google Scholar
• Wang JZ, Gao X, Wang ZH. The physiology and pathology of microtubule-associated protein tau. Essays Biochem. 2014;56:111–123.
   PubMed Web of Science ®Google Scholar
• Kumar P, Jha NK, Jha SK, et al. Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer’s disease. J Alzheimers Dis. 2015;43:341–361.
   PubMed Web of Science ®Google Scholar
• Liguori C, Stefani A, Sancesario G, et al. CSF lactate levels, tau proteins, cognitive decline: a dynamic relationship in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015;86:655–659.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Li L, Zhou TY, et al. Alzheimer’s disease progression model based on integrated biomarkers and clinical measures. Acta Pharmacol Sin. 2014;35:1111–1120.
   PubMed Web of Science ®Google Scholar
• Anderson LA, Egge R. Expanding efforts to address Alzheimer’s disease: the healthy brain initiative. Alzheimers Dement. 2014;10:453–456.
   Web of Science ®Google Scholar
• Davey DA. Alzheimer’s disease and vascular dementia: one potentially preventable and modifiable disease? Part II: management, prevention and future perspective. Neurodegener Dis Manag. 2014;4:261–270.
   PubMedGoogle Scholar
• de la Torre JC. Detection, prevention, and pre-clinical treatment of Alzheimer’s disease. J Alzheimers Dis. 2014;42:431–442.
   Google Scholar
• Tai LM, Koster KP, Luo J, et al. Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem. 2014;289:30535–30555.
   Web of Science ®Google Scholar
• Villeneuve S, Brisson D, Marchant NL, et al. The potential applications of Apolipoprotein E in personalized medicine. Front Aging Neurosci. 2014;6:154.
   PubMed Web of Science ®Google Scholar
• Awasthi M, Singh S, Pandey VP, et al. Alzheimer’s disease: an overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. J Neurol Sci. 2016;361:256–271.
   PubMed Web of Science ®Google Scholar
• Ma T, Tan MS, Yu JT, et al. Resveratrol as a therapeutic agent for Alzheimer’s disease. Biomed Res Int. 2014;2014:350516–350524.
   PubMedGoogle Scholar
• Mably AJ, Kanmert D, Mc Donald JM, et al. Tau immunization: a cautionary tale? Neurobiol Aging. 2015;36:1316–1332.
   PubMed Web of Science ®Google Scholar
• Avila J, Pallas N, Bolos M, et al. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies. Expert Opin Ther Targets. 2016:1–9. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Masand N, Gupta SP, Khosa RL, et al. Heterocyclic secretase inhibitors for the treatment of Alzheimer’s disease: an overview. Cent Nerv Syst Agents Med Chem. 2015. [Epub ahead of print].
   PubMedGoogle Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–321.
   PubMed Web of Science ®Google Scholar
• Lannfelt L, Moller C, Basun H, et al. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimers Res Ther. 2014;6:16–25.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu Y, Wang Z, et al. Clinical trials of amyloid-based immunotherapy for Alzheimer’s disease: end of beginning or beginning of end? Expert Opin Biol Ther. 2013;13:1515–1522.
   PubMed Web of Science ®Google Scholar
• Matsubara E, Takamura A, Okamoto Y, et al. Disease modifying therapies for Alzheimer’s disease targeting Aβ oligomers: implications for therapeutic mechanisms. Biomed Res Int. 2013;2013:984041–984057.
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–333.
   PubMed Web of Science ®Google Scholar
• Mably AJ, Liu W, Mc Donald JM, et al. Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol Dis. 2015;82:372–384.
   PubMed Web of Science ®Google Scholar
• de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology. 2000;54:S21–S23.
   PubMed Web of Science ®Google Scholar
• Rajput AH, Birdi S. Epidemiology of Parkinson’s disease. Parkinsonism Relat Disord. 1997;3:175–186.
   PubMedGoogle Scholar
• Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm. 2004;111:201–216.
   PubMed Web of Science ®Google Scholar
• Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinson’s disease. J Neuroimmune Pharmacol. 2013;8:189–201.
   PubMed Web of Science ®Google Scholar
• Figee M, de Koning P, Klaassen S, et al. Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder. Biol Psychiatry. 2014;75:647–652.
   PubMed Web of Science ®Google Scholar
• Meissner W, Harnack D, Paul G, et al.. Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats. Neurosci Lett. 2002;328:105–108.
   PubMed Web of Science ®Google Scholar
• Müller T. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2014;10:1–10.
   Google Scholar
• Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology. 2009;72:S32–S38.
   PubMed Web of Science ®Google Scholar
• Clarke CE, Patel S, Ives N, et al. Should treatment for Parkinson’s disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord. 2011;26:1187–1193.
   PubMed Web of Science ®Google Scholar
• Müller T, Pietsch A. Comparison of gait training versus cranial osteopathy in patients with Parkinson’s disease: a pilot study. NeuroRehabilitation. 2013;32:135–140.
   PubMed Web of Science ®Google Scholar
• Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease. Cochrane Database Syst Rev. 2013;9:CD002817.
   PubMed Web of Science ®Google Scholar
• van Nimwegen M, Speelman AD, Overeem S, et al. Promotion of physical activity and fitness in sedentary patients with Parkinson’s disease: randomised controlled trial. BMJ. 2013;346:f576–581.
   PubMed Web of Science ®Google Scholar
• Foster ER, Golden L, Duncan RP, et al. Community-based argentine tango dance program is associated with increased activity participation among individuals with Parkinson’s disease. Arch Phys Med Rehabil. 2013;94:240–249.
   PubMed Web of Science ®Google Scholar
• Gao Q, Leung A, Yang Y, et al. Effects of Tai Chi on balance and fall prevention in Parkinson’s disease: a randomized controlled trial. Clin Rehabil. 2014;28:748–753.
   PubMed Web of Science ®Google Scholar
• Müller T, Muhlack S. Effect of exercise on reactivity and motor behaviour in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81:747–753.
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr. 2001;113:851–854.
   PubMed Web of Science ®Google Scholar
• Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78:1096–1099.
   PubMed Web of Science ®Google Scholar
• Hauser R, Stocchi F, Rascol O, et al. Phase-3 clinical trials of adjunctive therapy with preladenant, an adenosine 2a antagonist, in patients with Parkinson’s disease. Neurology. 2014;82:P7.087.
   Google Scholar
• Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22:179–186.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson’s disease. Mov Disord. 2008;23:700–707.
   PubMed Web of Science ®Google Scholar
• Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord. 2014;20:947–955.
   PubMed Web of Science ®Google Scholar
• Roth NM, Saidha S, Zimmermann H, et al. Photoreceptor layer thinning in idiopathic Parkinson’s disease. Mov Disord. 2014;29:1163–1170.
   PubMed Web of Science ®Google Scholar
• Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368:610–622.
   PubMed Web of Science ®Google Scholar
• Müller T, Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother. 2013;13:707–718.
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Cossu G, Bandettini di Poggio M, et al. Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord. 2013;28:1391–1397.
   PubMed Web of Science ®Google Scholar
• Jugel C, Ehlen F, Taskin B, etal. Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs. PLoS One. 2013;8:e66639.
   PubMed Web of Science ®Google Scholar
• Müller T, van Laar T, Cornblath DR, et al. Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery.Parkinsonism Relat Disord. 2013;19:501–507.
   PubMed Web of Science ®Google Scholar